Drugs / ASP6294
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02681861 | Jan → Dec 2016 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03282318 | Sep 2017 → Mar 2019 | interstitial cystitis | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP6294 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02681861 ↗ |
| Route | Intravenous | “Intravenous (IV)” NCT02681861 ↗ |